Randomised EValuation of Therapies for microvAscuLar Injury in STEACS

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

Also called NCT06935383

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose other
Phase
Phase 2
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
CorFlow Therapeutics AG (from the registry)
Registry
  • NCT NCT06935383
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06935383. Randomized; single masking; primary purpose other. Start 2025-09 (anticipated); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
Acronym
REVITALISE
Condition
STEMI (ST Elevation MI)
Intervention (Device)
Therapeutic sequence
Intervention (Device)
Diagnostic sequence
Lead sponsor
CorFlow Therapeutics AG (class: industry)

Record details

Record id
cardio:ct-nct06935383
Content hash
f345af8841ad6e867ebaba8b607f1de73a4653717c4be834ee866fe7c50d2d61